Active Forum Topics | Getting Started | Interviews | EMR Forum | Medical | Billings | Press & News | Voice Recognition | The Water Cooler

emrupdate.com

Sign in | Join | Help

News » All Tags » Treatment (RSS)

emrupdate.com

Unbiased independant EMR discussions.

Browse by Tags

News

Home
About

Syndication

Recent Posts

Newly Identified Markers May Predict Who Will Respond to Breast Cancer Prevention Therapy
Some Patients With Treatment-resistant Colorectal Cancers May Have a New Option
RNA Interference Drug Demonstrated Activity and Safety in Phase I Trial
AACR Releases Policy Guidance on Tobacco and Cancer Clinical Trials
Cisplatin-resistant Cancer Cells Sensitive to Experimental Anticancer Drugs Called PARP Inhibitors

Tags

Archives

Newly Identified Markers May Predict Who Will Respond to Breast Cancer Prevention Therapy

PHILADELPHIA — Genetic variations, known as single nucleotide polymorphisms (SNPs), in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, according...

Published Thu, Jun 06 2013 10:00 AM by AACR News

Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, cancer prevention, American Association for Cancer Research, Cancer Discovery, women, journal, genes, tamoxifen, raloxifene, Dr. James N. Ingle, SERM, preventive treatment, ZNF423, CTSO, selective estrogen receptor modulator therapy
Some Patients With Treatment-resistant Colorectal Cancers May Have a New Option

PHILADELPHIA — A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression...

Published Sun, Jun 06 2013 9:00 AM by AACR News

Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, Cancer Discovery, colorectal cancer, KRAS, BRAF, treatment-resistant, NRAS, MET, anti-EGFR, Dr. Alberto Bardelli
RNA Interference Drug Demonstrated Activity and Safety in Phase I Trial

RNA interference drugs silence specific genes. Investigational drug silences the PLK1 gene involved in tumor growth. Most patients tolerated the drug well; some showed therapeutic benefit. WASHINGTON, D.C. — Early results from a phase I, first in...

Published Tue, Apr 04 2013 3:00 PM by AACR News

Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, Annual Meeting, AACR Annual Meeting 2013, 2013 Annual Meeting, phase I, RNA interference, Dr. Ramesh K. Ramanathan, RNAi
AACR Releases Policy Guidance on Tobacco and Cancer Clinical Trials

Statement calls for greater efforts in smoking cessation. Tobacco use should be evaluated as a confounding factor in clinical trials. Surveys show tobacco use is often not measured. WASHINGTON, D.C. — An American Association for Cancer Research...

Published Tue, Apr 04 2013 7:47 AM by AACR News

Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, tobacco, smoking, Clinical Cancer Research, policy statement, clinical trials, Annual Meeting, AACR Annual Meeting 2013, 2013 Annual Meeting, confounding factor
Cisplatin-resistant Cancer Cells Sensitive to Experimental Anticancer Drugs Called PARP Inhibitors

Cisplatin-resistant non-small cell lung cancer cells expressed high levels of hyperactivated PARP1. Cells succumbed to PARP inhibitors in vitro. PARP inhibitor slowed cisplatin-resistant tumor growth in mice. PHILADELPHIA — Poly (ADP-ribose) polymerase...

Published Wed, Apr 04 2013 12:05 AM by AACR News

Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, Cancer Research, journal, non-small cell lung cancer, NSCLC, cisplatin, PARP1, PARP inhibitor, cisplatin resistance, PAR, Dr. Guido Kroemer
Ganetespib Demonstrates Potency Against ALK-positive Lung Cancer and Overcomes Crizotinib Resistance

Ganetespib killed ALK-driven NSCLC cell lines more effectively than crizotinib. Displayed greater antitumor activity and prolonged survival in a mouse model. Potential as a new option for treating ALK-dependent lung cancers. PHILADELPHIA — A drug...

Published Tue, Mar 03 2013 1:00 PM by AACR News

Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, Cancer Discovery, journal, non-small cell lung cancer, anaplastic lymphoma kinase, ALK, NSCLC, ganetespib, resistance, crizotinib, Dr. David Proia
Functional Characteristics of Antitumor T Cells Change With Increasing Time After Therapeutic Transfer

Beneficial effect of genetically engineered antitumor T cells was transient. Functionality of T cells changed over time. Strategies are needed to sustain antitumor functionality. PHILADELPHIA — Scientists have characterized how the...

Published Thu, Mar 03 2013 10:00 AM by AACR News

Filed under: Press Releases, Research, Treatment, melanoma, Cancer, Media Materials, AACR, American Association for Cancer Research, Cancer Discovery, journal, immunotherapy, Dr. James R. Heath, T-cells, cell-based immunotherapy
Gene Profile May Help Identify Risk for Hormone-sensitive, Hormone-insensitive Breast Cancer

Levels of 13 genes elevated in unaffected breasts of women with hormone receptor-negative breast cancer. Eight of the genes were associated with lipid metabolism. Ability to identify those at risk may help tailor prevention strategies. PHILADELPHIA —...

Published Tue, Mar 03 2013 1:00 PM by AACR News

Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, prevention, Cancer Prevention Research, genetics, journal, hormone receptor-negative breast cancer, hormone receptor-positive breast cancer, breast cancer risk, Dr. Seema A. Khan, lipid metabolism
Biomarker May Identify Neuroblastomas With Sensitivity to BET Bromodomain Inhibitors

MYCN gene is commonly amplified in neuroblastoma and associated with poor prognosis. A BET bromodomain inhibitor downregulated MYCN expression. The drug prolonged survival in three animal models of MYCN-amplified neuroblastoma. PHILADELPHIA — Neuroblastoma...

Published Thu, Feb 02 2013 10:00 AM by AACR News

Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, Cancer Discovery, Stand Up To Cancer, SU2C, journal, Pediatric cancer, childhood cancer, neuroblastoma, biomarker, MYCN, Dr. Kimberly Stegmaier, BET bromodomain inhibitors
New Drug Combination Could Prevent Head and Neck Cancer in High-risk Patients

Preclinical combination of an EGFR inhibitor and a COX-2 inhibitor was effective. Advanced oral precancerous lesions were eliminated in three patients. Drug combination could be a new strategy to prevent head and neck cancers. PHILADELPHIA — A new...

Published Tue, Feb 02 2013 1:00 PM by AACR News

Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, Clinical Cancer Research, journal, high-risk, squamous cell carcinoma, head and neck cancer, clinical research, precancer, combination, Dr. Dong Moon Shin, oral precancerous lesions
Dear men: Are proton beams less toxic?

Published Thu, Jan 01 2013 2:19 PM by The Doctor Weighs In

Filed under: Treatment, Health care professionals, Health care & health policy, proton beam therapy, Medical Ethics, Paul Levy, Not Running a Hospital
Preventing Prostate Cancer Through Androgen Deprivation May Have Harmful Effects

Mice deficient in PTEN in the prostate developed stable precancers. Androgen deprivation promoted progression to invasive prostate cancer. Patients with PTEN-deficient prostate precancers may not benefit from androgen deprivation chemoprevention therapy...

Published Thu, Dec 12 2012 10:00 AM by AACR News

Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, cancer prevention, American Association for Cancer Research, prevention, genetics, Cancer Discovery, prostate cancer, journal, Dr. Thomas R. Roberts, precancer, androgen deprivation therapy
Hard-to-treat Myc-driven Cancers May Be Susceptible to Drug Already Used in Clinic

The mTORC1 inhibitor everolimus is used to treat various medical conditions. Everolimus prevented disease development in a mouse model of Myc-driven lymphoma. Treatment led to tumor regression in mice by inducing cellular senescence. PHILADELPHIA —...

Published Fri, Dec 12 2012 10:00 AM by AACR News

Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, American Association for Cancer Research, Cancer Discovery, journal, Everolimus, Target, Myc, Dr. Grant A. McArthur, mTORC1 inhibitor
New Screening Approach Identified Potential Drug Combinations for Difficult-to-treat Forms of Melanoma

High-throughput screen identified several drug combinations effective in vitro. Some combinations were effective against cell lines resistant to single agent used clinically. PHILADELPHIA — A novel approach to identifying potential anticancer drug...

Published Thu, Dec 12 2012 11:01 AM by AACR News

Filed under: Press Releases, Research, Treatment, melanoma, Cancer, Media Materials, AACR, American Association for Cancer Research, Cancer Discovery, journal, skin cancer, Dr. David F. Stern
Breast Cancer Genome Sequencing Identified HER2 Mutations as Targets for Drug Treatment

HER2 mutations occurred separately from HER2 gene amplification and DNA sequencing is required to detect them. HER2 mutations are rare but can be immediately treated with existing drugs. Phase II study using neratinib to treat HER2 mutations is under...

Published Fri, Dec 12 2012 8:30 AM by AACR News

Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, genetics, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, press conference, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, therapeutic target, neratinib, breast cancer genome, Dr. Ron Bose, HER2 mutations

1 2 3 4 5 Next > ... Last »

©2011 emrupdate.com. All rights reserved. | Acceptable Use Policy | Proud to be supported by the following EMR Vendor Sponsors:

eClinicalWorks | DescriptMED | EMR Experts | Medical Office Online | NextGen | TSI Healthcare

Getting Started | Forums | Medical | Blogs | Interviews | Unique Visits

ISP Providers | Timezones | Contact Sales